Alexza Pharmaceuticals Inc.
1020 East Meadow Circle
Palo Alto,
CA 94303
Phone: 650-687-3900
Fax: 650-687-3999
Web Site: http://www.alexza.com
| Alexza Pharmaceuticals, Inc., a development stage company, focuses on the development and commercialization of products for the treatment of acute and intermittent conditions primarily in the United States. Its technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The company has four product candidates in clinical development: AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches; AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder; AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia; and AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain. Its product candidate AZ-001 completed Phase IIb Clinical Trial; AZ-004 completed Phase IIa Clinical Trial; AZ-002 is in Phase IIa Clinical Trials; and AZ-003 completed a Phase I Clinical Trial. Alexza Pharmaceuticals has a development agreement with Autoliv ASP, Inc. for the development of heat packages that can be incorporated into proprietary single dose drug delivery device. The company, formerly known as FaxMed, Inc., was founded in 2000. FaxMed changed its name to Alexza Corporation in June 2001 and to Alexza Molecular Delivery Corporation in December 2001. Further, it changed its name to Alexza Pharmaceuticals, Inc. in July 2005. The company is based in Palo Alto, California. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Mr. Thomas B. King , 53
Chief Exec. Officer, Pres
|
$
454.00K |
$
1.25M |
Mr. August J. Moretti J.D.,
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
|
$
345.00K |
$
15.00K |
Dr. James V. Cassella Ph.D., 53
Sr. VP of R&D
|
N/A
|
N/A |
Dr. William C. Houghton M.D., 65
VP of Clinical Research & Regulatory Affairs
|
$
407.00K |
N/A |
Mr. Anthony Gordon Tebbutt , 60
Sr. VP of Bus. Devel. and Corp. Strategy
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-06
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
Profile
